ProCE Banner Activity

(Neo)Adjuvant Therapy in HER2-Negative Early Breast Cancer Treatment Selection Tool

Tool

Learn how 5 experts incorporate the latest evidence on (neo)adjuvant therapy into the management of HER2-negative breast cancer using this Interactive Decision Support Tool.

Released: October 06, 2023

Share

Faculty

Denise A. Yardley

Denise A. Yardley

Sarah Cannon Research Institute
Senior Investigator, Breast Cancer Research
Tennessee Oncology, PLLC
Nashville, Tennessee

Tanya Gupta

Tanya Gupta, MD

Clinical Assistant Professor
Breast Oncology
Stanford Healthcare
Palo Alto, California

Kevin Kalinsky

Kevin Kalinsky, MD, MS

Division Director, Medical Oncology
Professor, Department of Hematology and Medical Oncology
Winship Cancer Institute at Emory University
Atlanta, Georgia

Laura M. Spring

Laura M. Spring, MD

Breast Medical Oncologist
Mass General Cancer Center
Harvard Medical School
Boston, Massachusetts

Tiffany Traina

Tiffany Traina, MD

Associate Professor of Medicine
Weill Cornell Medical College
Vice Chair, Oncology Care
Department of Medicine/Breast Medicine Service
Memorial Sloan Kettering Cancer Center
New York, New York

Provided by

Provided by Clinical Care Options, LLC in partnership with Smart Patients.

ProCE Banner

Supporters

Supported by educational grants from AstraZeneca and Merck Sharp & Dohme LLC.

AstraZeneca

Merck Sharp & Dohme, LLC

Partners

Smart Patients

ProCE Banner

Faculty Disclosure

Primary Author

Tanya Gupta, MD

Clinical Assistant Professor
Breast Oncology
Stanford Healthcare
Palo Alto, California

Tanya Gupta, MD: consultant/advisor/speaker: AstraZeneca, Biotheranostics, Gilead.

Kevin Kalinsky, MD, MS

Division Director, Medical Oncology
Professor, Department of Hematology and Medical Oncology
Winship Cancer Institute at Emory University
Atlanta, Georgia

Kevin Kalinsky, MD, MS: consultant/advisor/speaker: 4D Pharma, AstraZeneca, Daiichi Sankyo, Genentech/Roche, Immunomedics, Lilly, Menarini, Merck, Mersana, Myovant, Novartis, Oncosec, Puma, SeaGen, Silicon Biosystems, Takeda; researcher: Ascentage, AstraZeneca, Genetech/Roche, Lilly, Novartis, SeaGen. 

Laura M. Spring, MD

Breast Medical Oncologist
Mass General Cancer Center
Harvard Medical School
Boston, Massachusetts

Laura M. Spring, MD: consultant/advisor/speaker: AstraZeneca, Daiichi Pharma, Lilly, G1 Therapeutics, Novartis, Puma; researcher (paid to institution): Genentech, Gilead, Lilly, Merck.

Tiffany Traina, MD

Associate Professor of Medicine
Weill Cornell Medical College
Vice Chair, Oncology Care
Department of Medicine/Breast Medicine Service
Memorial Sloan Kettering Cancer Center
New York, New York

Tiffany A. Traina, MD: consultant/advisor: Agendia, AstraZeneca, BioTheranostics, Blueprint Medicines, Daiichi Sankyo, Ellipses Pharma, Fuji Pharma, G1 Therapeutics, GE Healthcare, Genentech/Roche, Gilead Sciences, GlaxoSmithKline, Hengrui Pharmaceuticals, Infinity, Iteos Therapeutics, Merck, Novartis, Pfizer, SeaGen, TerSera; researcher (paid to institution): Astellas Pharma, AstraZeneca, Ayala Pharma, Carrick Pharma, Daiichi Sankyo, Genentech/Roche, Immunomedics, Innocrin, Pfizer.